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ABSTRACT: Looking for antihypertensive mechanisms beyond ACE inhibition, we assessed 21 
whether lactoferrin (LF)-derived peptides can act as receptor blockers to inhibit 22 
vasoconstriction induced by angiotensin II or endothelin-1. The lactoferricinB (LfcinB)-derived 23 
peptide LfcinB20-25 (RRWQWR), the low molecular weight LF hydrolysate (LFH<3 kDa), and two 24 
peptides identified in LFH<3 kDa (LIWKL and RPYL) were tested in ex vivo assays of vasoactive 25 
responses. The peptide RPYL was tested in radioligand receptor binding assays. Both LFH<3 26 
kDa and individual peptides inhibited angiotensin II-induced vasoconstriction. RPYL showed 27 
the highest ex vivo inhibitory effect and also inhibited binding of [125I]-(Sar1, Ile8)-Angiotensin II 28 
to AT1 receptors. By contrast, neither LFH<3kDa nor RPYL inhibited endothelin-1 and 29 
depolarization-induced vasoconstrictions. In conclusion, LF-derived peptides selectively inhibit 30 
angiotensin II-induced vasoconstriction by blocking angiotensin AT1 receptors. Therefore, 31 
inhibition of angiotensin II-induced vasocontriction is suggested as a mechanism contributing 32 
along with ACE inhibition to the antihypertensive effect of some LF-derived peptides. 33 
34 
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INTRODUCTION 38 
 Hypertension is probably the most important modifiable risk factor for cardiovascular 39 
disease, and its management includes not only pharmacological treatment but also life-style 40 
changes including physical activity and dietary habits.1 The increasing perception about the 41 
relation between food and health is fostering the development of functional foods providing 42 
health benefits beyond basic nutrition.2 Some food proteins contain embedded peptides that 43 
once released behave as bioactive peptides with different health promoting properties 44 
including blood pressure lowering effects.345 
 The renin angiotensin system (RAS) is one of the main targets for the treatment of 46 
hypertension. Its inhibition at three possible levels, angiotensin-converting enzyme (ACE), 47 
upstream renin activity or downstream angiotensin receptors, is the pharmacological basis for 48 
commonly used antihypertensive drugs.4 ACE inhibition is also the most aimed target for 49 
antihypertensive food-derived peptides developed as an alternative to drugs.5 Although 50 
different animal and plant proteins have been used, milk is the main source of 51 
antihypertensive ACE-inhibitory peptides reported to date.652 
 In contrast to casein, there was much less information about the potential of milk 53 
whey proteins as sources of antihypertensive peptides when some years ago we focused on 54 
whey protein lactoferrin (LF)7 and its well-known functional domain lactoferricin B (LfcinB).855 
First, we have shown that a set of peptides derived from LfcinB had inhibitory effects on in 56 
vitro ACE activity and ex vivo angiotensin I-induced ACE-dependent vasoconstriction,9 and 57 
were orally effective antihypertensive peptides in spontaneously hypertensive rats (SHRs).1058 
With regard to the parent protein, we have reported the inhibitory effects of a LF pepsin 59 
hydrolysate (LFH) on ACE activity and ACE-dependent vasoconstriction.11 Then, we have 60 
recently described that the ultrafiltered hydrolysate (LFH<3 kDa) showed increased inhibitory 61 
effect on ACE activity and orally antihypertensive effect in SHRs after both acute12 and 62 
chronic13 administration. Finally, we have isolated and identified novel non-LfcinB-derived 63 
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peptides with ACE-inhibitory and antihypertensive properties, which could contribute to the 64 
antihypertensive effects of LFH<3 kDa.1265 
 The search for in vitro ACE inhibition is the most common strategy in the selection of 66 
potential antihypertensive peptides derived from food proteins. However, it is difficult to 67 
establish a direct relationship between ACE-inhibitory effect in vitro and antihypertensive 68 
effect in vivo. On one hand, the in vitro ACE-inhibitory potency of food-derived peptides is 69 
around 1000 times lower than that of ACE-inhibitory drugs like captopril, but there are no 70 
substantial differences when their antihypertensive effects are compared.14 On the other 71 
hand, there is no correlation between in vitro and in vivo effects when different individual 72 
peptides or protein hydrolysates are compared. To explain these apparent discrepancies one 73 
should take into account both bioavailability issues and mechanisms of action other than ACE 74 
inhibition when bioactive peptides are assayed in vivo.15 Alternative antihypertensive 75 
mechanisms reported for food-derived bioactive peptides include short-term vasoactive 76 
mechanisms as well as long-term antioxidant and anti-inflammatory mechanisms.1677 
 Looking for antihypertensive mechanisms beyond ACE inhibition in milk protein 78 
derived bioactive peptides, we have shown that some LfcinB-derived peptides were dual 79 
vasopeptidase inhibitors. In addition to ACE, they inhibit endothelin-converting enzyme (ECE), 80 
a key enzyme of the endothelin system also involved in vascular tone and blood pressure 81 
regulation.17 We have also reported that orally effective antihypertensive LF hydrolysates may 82 
act as dual vasopeptidase (ACE/ECE) or as single ECE inhibitors with different 83 
antivasoconstrictor effects depending on the protease used to release bioactive peptides.18 In 84 
the present study, we aimed to assess whether LF derived peptides, in addition to inhibit the 85 
converting enzymes of the angiotensin and endothelin systems, can act as receptor blockers to 86 
inhibit vasoconstriction induced by angiotensin II or endothelin-1. For this purpose, we 87 
included in the study the LfcinB-derived peptide LfcinB20-25 (RRWQWR), the low molecular 88 
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weight LF pepsin hydrolysate LFH<3 kDa, and two peptides identified in LFH<3 kDa (LIWKL and 89 
RPYL), all of them with proven antihypertensive effects in SHRs. 90 
91 
MATERIALS AND METHODS 92 
Materials 93 
 Bovine lactoferrin (LF) was provided by FrieslandCampina Domo (Zwolle, The 94 
Netherlands). Porcine pepsin, porcine kidney ACE, human endothelin-1 (ET-1), captopril, 95 
valsartan and protease inhibitor cocktail were purchased from Sigma-Aldrich Química (Tres 96 
Cantos, Madrid, Spain). Angiotensin II was supplied by Calbiochem Co. (La Jolla, CA) and 97 
fluorescent ACE substrate o-aminobenzoylglycyl-p-nitrophenylalanylproline was from Bachem 98 
Feinchemikalien (Bubendorf, Switzerland). [125I]-(Sar1-Ile8)-Angiotensin II and angiotensin AT1 99 
receptor (human) membrane preparation were from PerkinElmer, Inc. (Waltham, MA), where 100 
membranes were prepared from transfected Chinese hamster ovary cells (cell line CHO-K1). 101 
 Peptides (LfcinB20-25, LIWKL and RPYL) were ordered at >95% purity from GenScript 102 
Corp. (Piscataway, NJ) wherein they were synthesized by solid phase methods using N-(9-103 
fluorenyl) methoxycarbonyl (Fmoc) chemistry. LfcinB20-25 was acetylated at the N-terminus and 104 
amidated at the C-terminus, because such modified peptide was used in our previous studies 105 
showing its vasoactive [Centeno et al., 2006] and antihypertensive [Ruiz-Giménez etal., 2010]106 
effects.  Actual peptide purities of supplied batches were 99.8% for LfcinB20-25, 97.7% for LIWKL 107 
and 99.5% for RPYL. Stock solutions of each peptide were prepared at 5 mM concentration in 108 
MilliQ water (Millipore Corp., Bedford, MA) and stored at ?20°C. LfcinB20-25 (RRWQWR) and 109 
LIWKL concentrations were determined on the basis of the extinction coefficient of W residues 110 
by measuring the absorbance at 280 nm (280 = 5600 M?1 cm?1 for W residue), while RPYL 111 
concentration was based on the dry weight of the peptide. 112 
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 A low molecular weight fraction of an LF hydrolysate obtained by enzymatic treatment 113 
with pepsin (LFH<3 kDa) was prepared as described previously,11,12 and the resulting permeate 114 
was freeze-dried and kept at room temperature until use. LFH<3 kDa was subjected to 115 
determination of protein content by the bicinchoninic acid method (BCA; Sigma-Aldrich 116 
Química) using BSA as standard and to in vitro assay of ACE-inhibitory potency (IC50) using the 117 
method described by Sentandreu and Toldrá19 as previously reported.12118 
119 
Animal Welfare 120 
 Rabbits were housed in temperature-controlled rooms (23°C) with 12 h light/dark 121 
cycles and consumed tap water and standard diet ad libitum. Euthanasia was carried out in 122 
accordance with the Spanish legislation on Protection of Animals used for Experimental and 123 
other Scientific Purposes. The study was approved by the Ethics Committee for Animal 124 
Welfare of the Hospital La Fe to be carried out in its accredited animal research facility 125 
(ES462500001001).  126 
127 
Isolation of Rabbit Carotid Arteries and Preparation of Membrane Microsomal Fraction 128 
 Thirty male New Zealand White rabbits (Technology Transferring Center, Polytechnic 129 
University of Valencia, Valencia, Spain), weighing 2.53 kg, were killed by injection of 25 mg/kg 130 
sodium thiopental and 1.5 ml of 10 mM KCl solution through the ear vein. A midline throat 131 
incision provided access to both common carotid arteries, which were dissected free and cut 132 
into four 4 mm-long segments each one for the ex vivo functional assays in organ bath. On the 133 
other hand, the membrane microsomal fraction from carotid arteries was obtained for 134 
radioligand binding assays according to Faber et al.20 with some modifications. Briefly, frozen 135 
tissue was pulverized in liquid N2, and homogenized (500 µL for 100 mg of tissue) in 4°C buffer 136 
(25 mM Tris-HCl, 1 mM EDTA, 2 mM MgCl2, and 100 mM KCl, pH 7.4) plus protease inhibitor 137 
cocktail (1% v/v) with an Ultra-Turrax T8 homogenizer (IKA-Werke, Staufen Germany) at 138 
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maximal speed (5 x 10 s). All procedures specified below were carried out at 4°C. The 139 
homogenate was subjected to 3 strokes at 4 watts in a Microson XL ultrasonic cell disruptor 140 
(Misonix, Farmingdale, NY), treated with 0.6 M KCl for 20 min to remove major contractile 141 
proteins, centrifuged at 1,000g for 10 min, the supernatant centrifuged at 10,000g for 10 min, 142 
and again the supernatant ultracentrifuged at 110,000g for 1 h. The final pellet was 143 
resuspended in storage buffer (50 mM Tris-HCl, 0.5 mM EDTA, 10 mM MgCl2, 10% sucrose, pH 144 
7.4, protease inhibitor cocktail) and kept at -80°C until used. The concentration of membrane 145 
protein was determined by the bicinchoninic acid method.146 
147 
Ex Vivo Functional Assays of Vasoactive Responses 148 
The arterial segments were mounted in an organ bath containing Ringer-Locke solution 149 
(120 mM NaCl, 5.4 mM KCl, 2.2 mM CaCl2, 1.0 mM MgCl2, 25 mM NaHCO3, and 5.6 mM 150 
glucose) for computer-assisted isometric tension recording, as described previously.9 The 151 
contractile capacity of every arterial segment was checked by exposure to 50 mM KCl Ringer-152 
Locke solution (NaCl replaced with an equimolar amount of KCl). Carotid arteries contracting 153 
less than 1 g were discarded. 154 
 To assess effects on angiotensin receptor-mediated vasoconstriction, every arterial 155 
segment was challenged with angiotensin II (1 µM). After washing out, each arterial segment 156 
was subjected to one of the following protocols: (i) control, a second challenge to angiotensin 157 
II to check for response reproducibility or (ii) treated, preincubation (20 min) with LFH<3 kDa 158 
(100 µg/mL), one of the LF-derived peptides (20 µM), the ACE-inhibitor drug captopril (0.1 M) 159 
or the angiotensin II AT1 receptor blocker drug valsartan (10 nM), and a second challenge to 160 
angiotensin II to check for their effect on angiotensin II-induced contraction. Concentration-161 
dependent effects were assessed for the LF-derived peptide RPYL (20-200 µM) and valsartan 162 
(10-100 nM). 163 
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 To assess effects on endothelin receptor-mediated vasoconstriction, every arterial 164 
segment was challenged with KCl (50 mM). After washing out, each arterial segment was 165 
subjected to one of the following protocols: (i) a challenge with endothelin-1 (10 nM) to obtain 166 
the control contractile response, or (ii) treated, preincubation (20 min) with LFH<3 kDa (100 167 
µg/mL), the LF-derived peptide RPYL (20 µM) or the angiotensin II AT1 receptor blocker drug 168 
valsartan (0.1 µM), and a challenge with endothelin-1 to check for their effect on endothelin-1-169 
induced contraction. 170 
Finally, some arterial segments were subjected to two successive challenges to 50 mM 171 
KCl with or without LFH<3 kDa (100 µg/mL), the LF-derived peptide RPYL (20 µM) or valsartan 172 
(0.1 µM) in between to check for non specific effects of the treatments on arterial contractile 173 
capacity. 174 
175 
Radioligand Receptor Binding Assays 176 
 Competition binding assays were carried out with both a membrane preparation 177 
containing human angiotensin AT1 receptor and a membrane microsomal fraction from rabbit 178 
carotid artery. The human receptor membrane preparation (0.6 µg protein) was incubated at 179 
27°C for 60 min in a total volume of 200 µL assay buffer (50 mM Tris-HCl, 5 mM MgCl2, pH 7.4) 180 
with [125I]-(Sar1, Ile8)-Angiotensin II (0.03 nM) and various concentrations of  unlabelled 181 
competitors. Experiments were terminated by rapid vacuum filtration through Whatman GF/C 182 
fiberglass filters (GE Healthcare Europe GmbH, Barcelona, Spain) presoaked in 0.5% BSA using 183 
a Brandel cell harvester (M24R, Valley Research Iberica, Madrid, Spain). The filters were then 184 
washed five times with 1 ml of ice-cold 50 mM Tris-HCl buffer (pH 7.4), and the filter-bound 185 
radioactivity was measured in a gamma counter (2480 WIZARD, PerkinElmer, Waltham, MA).  186 
Non-specific binding was determined in the presence of 1 µM unlabelled valsartan. Specific 187 
binding is defined as total binding minus non-specific binding. For the rabbit carotid artery 188 
membrane preparation, 40 µg protein and [125I]-(Sar1, Ile8)-Angiotensin II (0.06 nM) were used 189 
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instead. A full competition binding assay curve (1 pM - 1 µM) was carried out for valsartan, and 190 
selected concentrations of RPYL were assayed according to the vasoactive responses in the ex 191 
vivo functional assays. 192 
193 
Statistical Analyses 194 
 Values are expressed as the mean ± SEM. Unpaired Students t-test was used to assess 195 
differences between two groups. Analysis of variance (ANOVA) followed by Student-Newman-196 
Keuls test or Dunnetts test was used for multiple comparisons among more than two groups. 197 
P-values less than 0.05 were considered significant. The calculation of IC50 values was 198 
performed by nonlinear regression analysis. GraphPad Prism software (GraphPad Software 199 
Inc., La Jolla, CA) was used. 200 
201 
RESULTS 202 
Lactoferrin-Derived Peptides Inhibit Angiotensin II-Induced Vasoconstriction 203 
 Challenge of rabbit carotid arterial segments with a depolarizing solution (50 mM KCl) 204 
induced phasic contraction followed by active tone maintained until KCl wash-out. Average 205 
active tone amounted to 3424 ± 106 mg in all viable arterial segments included in the study (n 206 
= 200). 207 
 Angiotensin II (1 µM) induced phasic, transient contractions that were almost 208 
completely reproducible in two consecutive challenges to the same arterial segment (Figure 209 
1A). Average contractile response to the second challenge was 82 ± 2 % of the first response (n 210 
= 30). The inhibitory effects of the different treatments on angiotensin II-induced 211 
vasoconstriction were assessed as shown for RPYL in the representative recording of Figure 1B. 212 
LfcinB20-25 (20 µM), LFH<3 kDa (100 µg/mL), LIWKL (20 µM) and RPYL (20 µM) produced 213 
significant inhibition of angiotensin II-induced vasoconstriction when compared to control 214 
vasoconstriction (Figure 2A). The degree of inhibition ranged from 21 % response reduction 215 
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over the control conditions for the weakest LfcinB20-25 to 44 % response reduction for the 216 
strongest RPYL. Figure 2A also shows the lack of effect of the ACE-inhibitor captopril (0.1 M) 217 
on  angiotensin II-induced vasoconstriction and the significant inhibitory effect of the 218 
angiotensin II AT1 receptor blocker valsartan (10 nM).  Finally, concentration-dependent 219 
inhibitory effects on the contractile response to angiotensin II were shown for RPYL (20-200 220 
µM) as well as for valsartan (10-100 nM) (Figure 2B). 221 
222 
Lactoferrin-Derived Peptide RPYL Inhibits Binding of [125I]-(Sar1, Ile8)-Angiotensin II to AT1223 
Receptors224 
 The competitive angiotensin II AT1 receptor blocker valsartan (1 pM - 1 µM) induced 225 
concentration-dependent inhibition of [125I]-(Sar1, Ile8)-Angiotensin II (0.03 nM) specific binding 226 
to human angiotensin AT1 receptors (Figure 3A) with a calculated IC50 value of 0.79 ± 0.15 nM 227 
(n = 6). The peptide RPYL (3-300 µM) also induced significant concentration-dependent 228 
inhibition of [125I]-(Sar1, Ile8)-Angiotensin II specific binding to human angiotensin AT1 receptors 229 
(Figure 3B), amounting to 62 % binding inhibition at the highest RPYL concentration assayed 230 
(300 µM). On the other hand, RPYL (100 µM) also significantly reduced to 38.2 ± 5.0 % (n = 3, P231 
< 0.01) specific binding of [125I]-(Sar1, Ile8)-Angiotensin II (0.06 nM) to rabbit carotid artery 232 
angiotensin AT1 receptors.233 
234 
Lactoferrin-Derived Peptides Do Not Inhibit Endothelin-1 and Depolarization-Induced 235 
Vasoconstrictions236 
 Endothelin-1 (10 nM) induced slow contraction (Figure 4A) with maximum effect 237 
amounting to 108 ± 5 % relative to previous response to KCl, reached at 67 ± 6 min, with mean 238 
slope of 61 ± 7 mg/min (n = 16). The effects of the different treatments on endothelin-1-239 
induced vasoconstriction were assessed as shown for LFH<3 kDa in the representative 240 
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recording of Figure 4B. LFH<3 kDa (100 µg/mL), the peptide RPYL (20 µM) or valsartan (0.1 µM) 241 
did not induce significant modification of the contractile response to endothelin-1 (Table 1). 242 
 Finally, the effects of some treatments inhibiting angiotensin II-induced 243 
vasoconstriction were assayed also against KCl-induced vasoconstriction. In control conditions, 244 
the second vasoconstriction to KCl-induced depolarization was 116 ± 2 % of the first response 245 
in the same arterial segment (n = 19), and the responses to KCl were not significantly different 246 
after incubation with LFH<3 kDa (100 µg/mL), RPYL (20 µM) or valsartan (0.1 µM) (Table 1). 247 
248 
DISCUSSION 249 
We have found that some lactoferrin (LF)-derived antihypertensive peptides inhibit 250 
angiotensin II-induced vasoconstriction due to their blocking effect on angiotensin AT1 251 
receptors. This effect is selective for angiotensin AT1 receptors as endothelin-1-induced, ETA252 
receptor-mediated vasoconstriction is not inhibited, and no unspecific effects on 253 
depolarization-induced vasoconstriction are shown. 254 
We have previously reported that the low molecular weight LF hydroysate included in 255 
this study (LFH<3 kDa) shows antihypertensive effects in SHRs. Single-dose LFH<3 kDa induces 256 
acute blood pressure reduction in SHRs,12 and long-term intake attenuates progression of 257 
hypertension.13 LFH<3 kDa inhibits both in vitro ACE activity12 and ACE-dependent angiotensin 258 
I-induced vasoconstriction.18 The ACE inhibitory effect of LFH<3 kDa has been confirmed as an 259 
in vivo mechanism for the antihypertensive effect.13 The present results point to inhibition of 260 
angiotensin II-induced vasocontriction as a potential mechanism also contributing along with 261 
ACE inhibition to the antihypertensive effect of the hydrolysate. We have also previously 262 
shown that individual peptides embedded in different regions of the LF sequence, either 263 
derived from the lactoferricin B domain (LfcinB) or identified in LFH<3 kDa, are ACE inhibitors 264 
and have antihypertensive effects when acutely administered to SHRs.9,10,12 The present study 265 
shows that LfcinB20-25 also has a slight inhibitory effect on angiotensin II-induced 266 
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vasoconstriction. On the other hand, the inhibitory effects of individual peptides like LIWKL 267 
and to a higher extent RPYL on angiotensin II-induced vasoconstriction would contribute at 268 
least in part to the inhibitory effect of the whole hydrolysate LFH<3 kDa. 269 
The mechanism involved in the inhibitory effects of LF-derived peptides on angiotensin 270 
II-induced vasoconstriction has been further investigated using the most effective peptide 271 
RPYL. On one hand, our results show that the inhibitory effect of RPYL on angiotensin II-272 
induced vasoconstriction was concentration-dependent. Moreover, RPYL displaced the binding 273 
of [125I]-(Sar1, Ile8)-Angiotensin II to human angiotensin AT1 receptors also in a concentration-274 
dependent manner. These human recombinant receptors, expressed in transfected Chinese 275 
hamster ovary cells, are commonly used for AT1 receptor binding assays both in whole cells 276 
[Verheijen et al., 2000] and membrane preparations [Lee et al 2013]. Finally, the inhibitory 277 
effect of RPYL on [125I]-(Sar1, Ile8)-Angiotensin II specific binding was confirmed in membranes 278 
from rabbit carotid artery, the native tissue used in vasoconstriction experiments. All these 279 
results support an angiotensin AT1 receptor-blocking mechanism for the inhibitory effect of 280 
RPYL on angiotensin II-induced vasoconstriction. Angiotensin receptor blocker (ARB) drugs are 281 
a series of chemically related imidazol derivatives used in the clinical setting for hypertension 282 
treatment because of their ability to bind to angiotensin AT1 receptors, thereby inhibiting 283 
vasoconstriction and other cellular actions of angiotensin II.21,22 Valsartan, a member of this 284 
drug family23 has been used in our study as positive control both in vasoconstriction and 285 
binding experiments. Taking into account the concentrations used, RPYL was much less potent 286 
than valsartan in both experimental settings. 287 
The inhibitory effects of food-derived antihypertensive peptides on angiotensin II-288 
induced vasoconstriction have not been extensively studied, and when done no inhibition has 289 
been found. Others have reported the lack of effect of the milk-derived tripeptide IPP24 and 290 
the sardine muscle-derived dipeptide VY25 on angiotensin II-induced vasoconstriction. In a 291 
previous study with rationally designed heptapeptides, we found that the ACE inhibitor 292 
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antihypertensive heptapeptide PACEI50 (RKWHFLW) did not modify angiotensin II-induced 293 
vasoconstriction.26 With regard to LF-derived peptides, the crude LF pepsin hydrolysate before 294 
ultrafiltration (LFH) did not inhibit angiotensin II-induced vasoconstriction, did not modify 295 
blood pressure in SHRs, and showed much less inhibitory potency on ACE than LFH<3 kDa,11,12296 
thus indicating that the antihypertensive effects of the LF hydrolysate are due to the bioactive 297 
properties of its low molecular weight peptides like LIWKL and RPYL. 298 
To the best of our knowledge, the present study for the first time shows the ability of 299 
antihypertensive bioactive peptides to inhibit angiotensin II-induced vasoconstriction by an 300 
angiotensin AT1 receptor blocking mechanism. With regard to non peptide substances, 301 
inhibition of angiotensin II-induced vasoconstriction has been reported to underlie the 302 
antihypertensive effects of compounds like nitro-oleic acid, a NO-derived fatty acid,27 and 303 
especially plant extracts used in folk medicine.28-32 Moreover, proanthocyanidins and alkaloids 304 
from some plant extracts are angiotensin AT1 receptor binding compounds.33-35 On the other 305 
hand, inhibitory effects on renin activity, the rate limiting enzyme upstream the RAS,36 have 306 
been reported for hemp seed protein hydrolysates,37 flaxseed protein hydrolysate fractions38307 
and peptides from pea protein hydrolysates,39 as well as for peptides from a protein 308 
hydrolysate of the macroalga Palmaria palmate.40 In most of these cases, inhibitory effects 309 
were observed on both renin and ACE activities.37-39 Therefore, bioactive peptides with 310 
antihypertensive potential can be multifunctional peptides inhibiting more than one of the RAS 311 
steps: generation of angiotensin I from angiotensinogen by renin, generation of vasoactive 312 
angiotensin II from angiotensin I by ACE, or activation of the AT1 receptor by angiotensin II.36313 
The endothelin system, similar to the RAS, is another peptidic system with an 314 
increasingly recognized role in blood pressure regulation and hypertension pathophysiology.41315 
Of particular relevance in the cardiovascular system, endothelin-1 has powerful 316 
vasoconstrictor and pressor properties. The gene product preproendothelin-1 is cleaved by a 317 
furin-like endopeptidase to form a biologically inactive intermediate termed big endothelin-1. 318 
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Next, big ET-1 is cleaved by an endothelin-converting enzyme (ECE) to form endothelin-1, 319 
which binds to vascular ETA receptors to induce vasoconstriction.42 Both AT1 and ETA receptors 320 
belong to the class 1 of G protein-coupled receptors,43 and dual action AT1 and ETA receptor 321 
antagonists reduce blood pressure in experimental hypertension.44 Moreover, angiotensin AT1 322 
receptor binding alkaloids from the root of Bocconia frutescens also show weaker binding to 323 
endothelin ETA receptors.34 Our results show that neither LFH<3 kDa nor RPYL, the peptide 324 
with the highest inhibitory effect on angiotensin II-induced vasoconstriction, modified the 325 
vasoconstriction induced by endothelin-1, thus supporting the selective effects of LF-derived 326 
peptides on the AT1 receptor. In a previous study, we reported that LfcinB-derived peptides 327 
hinder endothelin-1 generation by inhibiting ECE activity but do not act on downstream ETA328 
receptors or intracellular signal transduction mechanisms leading to vasoconstriction.17329 
Some considerations have to be made regarding availability of LF-derived peptides 330 
both in the present experiments and in in vivo circumstances. On one hand, peptidases are 331 
present in the wall of blood vessels, both in the endothelial layer and in the smooth 332 
muscle.[Palmieri et al., 1989] In addition to ACE[Centeno et al., 2006] and ECE[Fernández-333 
Musoles et al., 2010] activities previously shown in the isolated rabbit carotid artery used in 334 
our ex vivo assays, some other vascular peptidases hydrolyze endogenous vasoactive peptides 335 
thus interfering with their biological effects.[Ryan, 1989; Rouissi et al., 1990] A possible 336 
hydrolytic effect of vascular peptidases on LF-derived peptides during their incubation with the 337 
carotid arteries cannot be dismissed. On the other hand, depending on the acid base nature of 338 
their amino acid residues, peptide-peptide ionic interactions can occur to form quite stable 339 
non covalent complexes.[Woods & Huestis, 2001] In our study, interaction between LF-derived 340 
peptides and angiotensin II to form peptide complexes unable to bind to AT1 receptors has not 341 
been assessed. The influence of such mechanism on availability of LF-derived peptides and 342 
their inhibitory effects on angiotensin II-induced contraction cannot be discarded. Finally, 343 
bioavailability of peptides after oral administration is needed to guarantee bioactivity.[14] The 344 
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few bioavailability studies performed in vivo show the detection of VPP and IPP in plasma in 345 
picomolar to nanomolar concentrations[Foltz et al., 2007] with elimination half-lives of about 2 346 
min[Van der Pijl et al., 2008]. The low bioavailability found for most natural peptides raises 347 
questions as to whether those peptides lower blood pressure only via an ACE-inhibiting 348 
mechanism in blood vessels. Although plasma levels of the peptides were no measured in our 349 
studies reporting the antihypertensive effects of orally administered LFcin B20-25, LIWKL and 350 
RPYL,[Ruiz-Giménez et al., 2010; 2012] we showed RYPL to be particularly resistant to 351 
simulated gastrointestinal digestion[Ruiz-Giménez et al., 2012]. Moreover, RPYL and the other 352 
LF-derived peptides add their inhibitory effects on angiotensin II effects to ACE inhibition.   353 
 In conclusion, LF-derived peptides released from different regions of the protein inhibit 354 
angiotensin II-induced vasoconstriction by blocking angiotensin AT1 receptors. The lack of 355 
effects on endothelin-1-induced, ETA receptor-mediated vasoconstriction as well as on 356 
depolarization-induced vasoconstriction points to a selective effect of the peptides. Therefore, 357 
inhibition of angiotensin II-induced vasocontriction is suggested as a potential mechanism also 358 
contributing along with ACE inhibition to the antihypertensive effect of some LF-derived 359 
peptides.360 
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ABBREVIATIONS USED 361 
ACE, angiotensin-converting enzyme; AT1, angiotensin receptor 1; ECE, endothelin-converting 362 
enzyme; ET-1, endothelin-1; ETA, endothelin receptor A; IC50, half-maximal effective 363 
concentration; LF, lactoferrin; LfcinB, lactoferricin B; LFH, lactoferrin hydrolysate; RAS, renin 364 
angiotensin system; SHR, spontaneously hypertensive rat365 
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FIGURE CAPTIONS520 
521 
Figure 1. Typical vasoconstrictor effects of angiotensin II (Ang II) in carotid artery segments 522 
isolated from New Zealand White rabbits. (A) Successive vasoconstrictions to Ang II in control 523 
conditions. (B) Effect of the LF-derived peptide RPYL on Ang II-induced vasoconstriction.524 
525 
Figure 2. Inhibitory effects of lactoferrin-derived peptides on angiotensin II (Ang II)-induced 526 
vasoconstriction in carotid artery segments isolated from New Zealand White rabbits. (A) 527 
LfcinB20-25, LFH<3 kDa, the LF-derived peptides LIWKL and RPYL, the ACE-inhibitor captopril, 528 
and the Ang II AT1 receptor blocker valsartan were applied before the second addition of Ang II 529 
(1 M). (B) Concentration-dependent inhibitory effects of RPYL and valsartan on Ang II-induced 530 
vasoconstriction. Vasoconstrictor responses are expressed as a percentage of previous Ang II-531 
induced contraction. Data are the mean ± SEM from (n) arterial segments. *P < 0.05 and **P < 532 
0.01 compared with Ang II alone (control), respectively. ## P < 0.01 compared with RPYL (20 533 
M), and § P < 0.05 compared with valsartan (10 nM).534 
535 
Figure 3. Inhibition of [125I]-(Sar1,Ile8)-Angiotensin II specific binding to a membrane 536 
preparation from CHO-K1 cells expressing the human angiotensin AT1 receptor. Non-specific 537 
binding was 29.4 ± 4.1%, mean ± SEM from nine independent experiments (each performed in 538 
duplicate or triplicate). (A) Sigmoidal curve for concentration-dependent inhibitory effects of 539 
the angiotensin II AT1 receptor blocker valsartan. Data are the mean ± SEM from six 540 
independent experiments (each performed in duplicate or triplicate). (B) Concentration-541 
dependent inhibitory effects of the LF-derived peptide RPYL. Data are the mean ± SEM from at 542 
least three independent experiments (each performed in duplicate or triplicate). *P < 0.05 and 543 
**P < 0.01 compared with [125I]-(Sar1,Ile8)-Angiotensin II alone (control), respectively. # P < 0.05 544 
compared with RPYL (30 M). 545 
26 
Figure 4. Typical vasoconstrictor effects of endothelin-1 (ET-1) in carotid artery segments 546 
isolated from New Zealand White rabbits. (A) Vasoconstriction to high-KCl and to ET-1 in 547 
control conditions. (B) Effect of LFH<3 kDa on ET-1-induced vasoconstriction. 548 
27 
Table 1. Vasoconstrictor responses of carotid artery segments isolated from New Zealand 
White rabbits to endothelin-1 and KCl-induced depolarization, in control conditions and after 
treatment with LFH<3 kDa, the LF-derived peptide RPYL, the angiotensin II AT1 receptor 
blocker valsartan, and the selective ETA endothelin receptor antagonist BQ-123 . 
 Endothelin-1 (10 nM) KCl (50 mM) 
Control 
LFH<3 kDa (100 g/mL) 
124 ± 2 (3) 
113 ± 6 (9) 
117 ± 2 (8) 
113 ± 2 (8) 
Control 
RPYL (20 M) 
106 ± 11 (7) 
93 ± 5 (8) 
109 ± 2 (7) 
109 ± 3 (7) 
Control 
Valsartan (0.1 M) 
103 ± 3 (6) 
109 ± 3 (16) 
124 ± 8 (4) 
128 ± 5 (12) 
Control 
BQ-123 (1 µM) a
123 ± 7 (12) 
49 ± 3 (8)** 
n.d. 
Vasoconstrictor responses are expressed as a percentage of previous KCl-induced contraction. 
Data are the mean ± SEM from (n) arterial segments (n.d., not determined). 
aTaken from Fernández-Musoles et al.17
** Significantly different from control, P < 0.01. Unpaired Students t-test. 
